JP7045327B2 - 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン - Google Patents

抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン Download PDF

Info

Publication number
JP7045327B2
JP7045327B2 JP2018556446A JP2018556446A JP7045327B2 JP 7045327 B2 JP7045327 B2 JP 7045327B2 JP 2018556446 A JP2018556446 A JP 2018556446A JP 2018556446 A JP2018556446 A JP 2018556446A JP 7045327 B2 JP7045327 B2 JP 7045327B2
Authority
JP
Japan
Prior art keywords
bdca2
seq
concentration
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018556446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520316A (ja
JP2019520316A5 (enExample
Inventor
マーク アール． エイチ． クレブス，
デイビッド ダイ，
シャンタヌ スレ，
ダニア ラバー，
デイビッド マーティン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2019520316A publication Critical patent/JP2019520316A/ja
Publication of JP2019520316A5 publication Critical patent/JP2019520316A5/ja
Priority to JP2022043702A priority Critical patent/JP2022084782A/ja
Application granted granted Critical
Publication of JP7045327B2 publication Critical patent/JP7045327B2/ja
Priority to JP2024001801A priority patent/JP2024038308A/ja
Priority to JP2026042524A priority patent/JP2026094462A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018556446A 2016-04-28 2017-04-27 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン Active JP7045327B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022043702A JP2022084782A (ja) 2016-04-28 2022-03-18 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2024001801A JP2024038308A (ja) 2016-04-28 2024-01-10 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2026042524A JP2026094462A (ja) 2016-04-28 2026-03-16 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
US62/328,959 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022043702A Division JP2022084782A (ja) 2016-04-28 2022-03-18 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン

Publications (3)

Publication Number Publication Date
JP2019520316A JP2019520316A (ja) 2019-07-18
JP2019520316A5 JP2019520316A5 (enExample) 2020-05-14
JP7045327B2 true JP7045327B2 (ja) 2022-03-31

Family

ID=58672794

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018556446A Active JP7045327B2 (ja) 2016-04-28 2017-04-27 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2022043702A Pending JP2022084782A (ja) 2016-04-28 2022-03-18 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2024001801A Pending JP2024038308A (ja) 2016-04-28 2024-01-10 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2026042524A Pending JP2026094462A (ja) 2016-04-28 2026-03-16 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022043702A Pending JP2022084782A (ja) 2016-04-28 2022-03-18 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2024001801A Pending JP2024038308A (ja) 2016-04-28 2024-01-10 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2026042524A Pending JP2026094462A (ja) 2016-04-28 2026-03-16 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン

Country Status (14)

Country Link
US (2) US20190284281A1 (enExample)
EP (1) EP3448425A1 (enExample)
JP (4) JP7045327B2 (enExample)
KR (5) KR20220028150A (enExample)
CN (2) CN109475623B (enExample)
AU (2) AU2017258191B2 (enExample)
CA (1) CA3022116A1 (enExample)
CO (1) CO2018012506A2 (enExample)
EA (1) EA201892443A1 (enExample)
IL (2) IL262514B2 (enExample)
MA (1) MA44763A (enExample)
MX (3) MX2018012945A (enExample)
PH (1) PH12018502278A1 (enExample)
WO (1) WO2017189827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49962A (fr) * 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
ES3014697T3 (en) 2018-07-19 2025-04-24 Ichnos Sciences S A Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
CN116963716A (zh) * 2020-12-03 2023-10-27 渤健马萨诸塞州股份有限公司 治疗皮肤型红斑狼疮和系统性红斑狼疮的方法
KR20230022786A (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
WO2024140838A1 (zh) * 2022-12-28 2024-07-04 映恩生物制药（苏州）有限公司 抗bdca2抗体-药物偶联物及其用途
IL327431A (en) * 2023-09-28 2026-05-01 Nanjing Leads Biolabs Co Ltd BDCA2 monoclonal antibody, fusion protein consisting of the same antibody and TACI and method and use thereof
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524602A (ja) 2003-04-04 2007-08-30 ジェネンテック・インコーポレーテッド 高濃度抗体及びタンパク質製剤
JP2016505556A (ja) 2012-12-10 2016-02-25 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗血液樹状細胞抗原２抗体およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524602A (ja) 2003-04-04 2007-08-30 ジェネンテック・インコーポレーテッド 高濃度抗体及びタンパク質製剤
JP2016505556A (ja) 2012-12-10 2016-02-25 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗血液樹状細胞抗原２抗体およびその使用

Also Published As

Publication number Publication date
IL262514A (en) 2018-12-31
MX2025000037A (es) 2025-02-10
IL262514B2 (en) 2025-12-01
JP2019520316A (ja) 2019-07-18
BR112018072125A2 (pt) 2019-03-19
KR102366547B1 (ko) 2022-02-23
CN109475623B (zh) 2023-05-26
IL262514B1 (en) 2025-08-01
MX2018012945A (es) 2019-03-06
MA44763A (fr) 2019-03-06
KR20240159012A (ko) 2024-11-05
AU2017258191A1 (en) 2018-11-15
CN109475623A (zh) 2019-03-15
IL321561A (en) 2025-08-01
CN116850282A (zh) 2023-10-10
NZ787392A (en) 2025-08-29
JP2024038308A (ja) 2024-03-19
MX2023008075A (es) 2023-07-18
AU2017258191B2 (en) 2024-06-13
EP3448425A1 (en) 2019-03-06
KR20240033168A (ko) 2024-03-12
NZ747504A (en) 2025-08-29
CO2018012506A2 (es) 2018-12-14
AU2024203240A1 (en) 2024-06-13
PH12018502278A1 (en) 2019-09-09
JP2022084782A (ja) 2022-06-07
US20190284281A1 (en) 2019-09-19
KR20190002563A (ko) 2019-01-08
CA3022116A1 (en) 2017-11-02
EA201892443A1 (ru) 2019-04-30
WO2017189827A1 (en) 2017-11-02
KR20250088784A (ko) 2025-06-17
KR20220028150A (ko) 2022-03-08
JP2026094462A (ja) 2026-06-09
US20250289895A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
JP2022084782A (ja) 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP6949718B2 (ja) 抗ｐｄ−１抗体と他の抗体の組み合わせを含む組成物
TWI835808B (zh) 抗pd-1抗體及其用途
CN104398471A (zh) 稳定的抗体组合物和用于稳定其的方法
EP4095158A1 (en) Pharmaceutical composition containing anti-btla antibody and use thereof
EP4403573A1 (en) Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
JP2020519634A (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
CN111808190A (zh) 结合pd-1的抗体
CN112804989A (zh) 抗fgfr2抗体制剂
WO2023240223A2 (en) Anti-igf-1r antibody compositions
US20260139047A1 (en) Pharmaceutical composition containing fusion protein
WO2023134771A1 (zh) 抗ctla-4抗体药物组合物及其用途
WO2025098341A1 (en) IL-7Ra TARGETING ANTIBODIES AND USES THEREOF
WO2023198115A1 (en) Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereof
BR122024003611A2 (pt) Composições farmacêuticas, anticorpo anti-bdca2, uso do mesmo, e seringa ou bomba
BR112018072125B1 (pt) Composição farmacêutica e seringa, injetor ou bomba
EA043069B1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
EA053327B1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
HK40052955A (zh) 抗fgfr2抗体制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220318

R150 Certificate of patent or registration of utility model

Ref document number: 7045327

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250